What Mycenax Biotech does

Mycenax Biotech Inc. is a Taiwan-based biologics Contract Development and Manufacturing Organization (CDMO) founded in 2001 and publicly listed on the Taipei Exchange (TPEx) under ticker 6541. The company operates two PIC/S GMP-compliant manufacturing facilities located in Zhunan, Miaoli (Taiwan), supplemented by corporate headquarters in Zhubei City, Hsinchu County and a business center in Taipei. Its facilities have been successfully inspected by EMA (Europe), PMDA (Japan), and Health Canada, providing regulatory access to three major international markets.

The company provides end-to-end CDMO services spanning drug feasibility assessment, cell line development, upstream and downstream process development, analytical method development, formulation development, GMP drug substance manufacturing, aseptic fill-finish, and process characterization and validation. Core capabilities span mammalian biologics (monoclonal and bispecific antibodies, recombinant proteins) via the proprietary NaxLeap™ transposon system, microbial biologics (plasmid DNA, recombinant proteins, enzymes) via PlasMX™, antibody-drug conjugates via Multi-Arm Linker technology, and cell and gene therapies including ExoMX™ exosome manufacturing and allogeneic immune cell solutions. Revenue is generated primarily through project-based CDMO service contracts (fee-for-service / managed services), supplemented by technology licensing of proprietary platforms such as NaxLeap™ and PlasMX™.

Mycenax targets enterprise pharmaceutical and biotech clients globally with project-specific quotes rather than standardized pricing. The company employs 101–250 people and pursues a B2B field sales motion with content marketing (white papers), industry conference participation, and direct client engagement across Traditional Chinese, English, and Japanese language channels. In October 2025, Mycenax entered a joint venture with Alfresa Holdings, Kidswell Bio, and Kaiom Biosciences to establish biosimilar API and formulation manufacturing capacity in Japan, signaling strategic geographic expansion into the Japanese market where it has existing PMDA inspection approval and prior JCR Pharmaceuticals investment backing.

Name

Mycenax Biotech

Legal name

Mycenax Biotech Inc.

Website

https://mycenax.com.tw

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

101–250 employees

Short description

Mycenax Biotech is a Taiwan-based biologics CDMO operating two PIC/S GMP facilities, providing end-to-end process development and GMP manufacturing of antibodies, ADCs, cell/gene therapies, and plasmid DNA for global pharmaceutical and biotech clients.

Ownership category

akta.pro rank

Product category

Biologics Contract Manufacturing

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

Keywords

• Biologics CDMO services
• Contract manufacturing
• Cell line development
• Plasmid DNA manufacturing
• Gene therapy production

Headquarters

HQ city

Zhuan

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. CDMO Services: Contract development and manufacturing organization providing fee-for-service biological drug development and manufacturing from DNA to GMP production, including process development, drug substance manufacturing, and aseptic fill-finish services
2. Technology Licensing: Licensing of proprietary technology platforms including NaxLeap™ transposon system and PlasMX™ plasmid DNA manufacturing to clients

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Mycenax Biotech is a Taiwan-based biologics Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services spanning cell line development, process development, and cGMP-compliant manufacturing of biologics, plasmid DNA, and gene therapy products. The company operates two PIC/S GMP-compliant facilities with global regulatory approvals and supports pharmaceutical and biotech clients from DNA to commercial GMP supply.

Product overview

Mycenax Biotech is a Contract Development and Manufacturing Organization (CDMO) specializing in biologics and biosimilars, offering end-to-end services from process development to cGMP-compliant manufacturing. The company operates two PIC/S GMP-compliant facilities providing comprehensive manufacturing solutions from drug substance (DS) to drug product (DP). Core capabilities span mammalian and microbial biopharmaceutical production, including bispecific/multispecific antibodies (via NaxLeap™ Transposon System), antibody-drug conjugates (ADCs via Multi-Arm Linker technology), and cell & gene therapies (including ExoMX™ exosome manufacturing and Allogeneic Immune Cell Solutions). Plasmid DNA is supported through the PlasMX™ platform. The integrated service portfolio covers cell line development, process characterization, analytical services, and aseptic fill-finish operations.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell Line Development Services Generation of stable, high-expressing mammalian cell lines for biopharmaceutical production, leveraging the proprietary NaxLeap™ transposon-based platform to accelerate clone selection and expression optimization for pharma and biotech clients.
• Process Development Services Upstream and downstream process development, scale-up, and optimization for biologics and plasmid DNA programs, designed to deliver robust, scalable, and GMP-transferable processes for clients' drug candidates.
• cGMP Biologics Manufacturing Clinical and commercial-scale cGMP manufacturing of biologics performed at PIC/S GMP-compliant facilities with global regulatory approvals, supporting antibody and recombinant protein programs for pharma clients.
• Plasmid DNA Manufacturing (PlasMX™) End-to-end plasmid DNA manufacturing service for gene therapy, cell therapy, and nucleic acid vaccine developers, covering process development through cGMP production using the proprietary PlasMX™ platform.
• Gene Therapy Manufacturing Services Process development and cGMP manufacturing services for gene therapy products, leveraging the company's plasmid DNA expertise and PIC/S GMP manufacturing capabilities to support advanced therapy developers.

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• Alfresa HoldingscoreStrategic or Co-development Partner · 1 October 2025Mycenax Biotech joined Alfresa Holdings, Kidswell Bio, and Kaiom Biosciences in October 2025 to form a joint venture strengthening domestic biosimilar API and formulation manufacturing in Japan. This partnership aligns with Japan's government allocation of USD 100 million to support regenerative medicine and sterile pharmaceutical production infrastructure.
• Kidswell BiocoreStrategic or Co-development Partner · 1 October 2025Mycenax Biotech joined Alfresa Holdings, Kidswell Bio, and Kaiom Biosciences in October 2025 to form a joint venture strengthening domestic biosimilar API and formulation manufacturing in Japan.
• Kaiom BiosciencescoreStrategic or Co-development Partner · 1 October 2025Mycenax Biotech joined Alfresa Holdings, Kidswell Bio, and Kaiom Biosciences in October 2025 to form a joint venture strengthening domestic biosimilar API and formulation manufacturing in Japan.

Scale indicators3 records

Recent moves2 records

Expansion highlights5 records

Emerging players

• Celltrion: South Korean biosimilars developer and contract manufacturer of mammalian-expressed mAbs. Comparable as an Asia-based biologics manufacturer operating in the biosimilar space, though Celltrion is more product-owner than pure CDMO.

Broad incumbents

• Samsung Biologics: South Korea-based large-scale biologics CDMO providing mammalian cell-derived mAb/bispecific manufacturing and fill-finish services. Competes head-to-head in mammalian biologics CDMO and shares the Asian manufacturing base advantage with Mycenax.
• Lonza Biologics: Swiss-headquartered leading global CDMO with mammalian and microbial biologics, cell and gene therapy, and integrated drug substance-to-drug product capabilities. Directly comparable end-to-end CDMO model with global regulatory footprint exceeding Mycenax's.
• WuXi Biologics: Hong Kong-listed global biologics CDMO offering mammalian cell culture, bispecific antibodies, ADC, and viral vector services across multiple mega-plants. Directly comparable as a biologics CDMO serving pharma/biotech clients with end-to-end drug substance development, though at materially larger scale than Mycenax.
• Catalent: US-based large CDMO offering biologics cell line development, fill-finish, and ADC services. Comparable in biologics and ADC modalities, particularly overlapping with Mycenax's bispecific antibody and ADC manufacturing services.
• Boehringer Ingelheim BioXcellence: German pharma's biopharmaceutical contract manufacturing arm offering mammalian and microbial biologics, fill-finish, and cell/gene therapy services. Comparable as a globally diversified biologics CDMO serving pharma clients with integrated solutions.

Direct peers

• AGC Biologics: CDMO offering mammalian and microbial biologics, gene therapy, and cell therapy manufacturing from sites in the US, Europe, and Asia (including Japan/India). Closely comparable mid-size biologics CDMO with multi-modality capabilities similar to Mycenax's portfolio.
• KBI Biopharma: US-based biologics CDMO providing mammalian cell culture, microbial fermentation, and analytical services. Comparable mid-size CDMO with similar service scope (mammalian, microbial, analytical) to Mycenax's integrated biologics offerings.

Regional players

• Bora Pharmaceuticals: Taiwan-based CDMO specializing in sterile fill-finish, oral solid dose, and biologics services. Comparable as a Taiwan-headquartered CDMO serving regional pharma clients, though Mycenax is more biologics-focused while Bora spans small molecules and injectables.

Others

• JCR Pharmaceuticals: Japanese specialty biopharmaceutical company and Mycenax's 2022 investor/strategic partner, focused on biosimilars and rare disease biologics. Comparable as a Japan-connected biologics player, and a direct business partner via funding and JV context rather than head-to-head CDMO competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/mycenaxbiotechinc
• LinkedInlinkedin.com/company/mycenax

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mycenax Biotech